Regenxbio (RGNX) Cash from Operations (2014 - 2025)

Regenxbio's Cash from Operations history runs 12 years deep, the most recent figure standing at 52290000.0 for Q4 2025.

• On a quarterly basis, Cash from Operations fell 65.35% year-over-year to 52290000.0 in Q4 2025; TTM through Dec 2025 was 123963000.0, a 28.4% increase from a year earlier, with the FY2025 full-year figure at 123963000.0, up 28.4% from the prior year.
• Cash from Operations rose to 52290000.0 in Q4 2025 per RGNX's latest filing, from 55960000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 341497000.0 in Q4 2021 and bottomed at 80918000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 46409500.0 (2023), against an average of 25205400.0.
• Across the five-year window, Cash from Operations surged 765.25% in 2021 and tumbled 111.53% in 2022, its largest moves.
• Year by year, Cash from Operations stood at 341497000.0 in 2021, then tumbled by 111.53% to 39372000.0 in 2022, then decreased by 3.53% to 40760000.0 in 2023, then advanced by 22.41% to 31624000.0 in 2024, then tumbled by 65.35% to 52290000.0 in 2025.
• Per Business Quant, the three latest RGNX Cash from Operations figures stand at 52290000.0 (Q4 2025), 55960000.0 (Q3 2025), and 49342000.0 (Q2 2025).